Online citations, reference lists, and bibliographies.
← Back to Search

Prise En Charge Du Mésothéliome Pleural Malin En 2013

J. Margery, W. Gaspard, I. Ngampolo, H. Souhi, H. Floch, F. Riviere, C. Marotel, D. Planchard, F. Vaylet
Published 2013 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Resume Le mesotheliome malin pleural (MPM) est une tumeur rare et agressive, souvent consecutive a une exposition professionnelle a l’amiante. La symptomatologie clinique et radiologique est aspecifique. Le diagnostic est apporte par l’histologie a partir de biopsies pleurales obtenues par thoracoscopie. L’irradiation des orifices chirurgicaux diagnostiques est validee par les recommandations francophones. La chirurgie par pleuropneumonectomie elargie ou par pleurectomie/decortication n’est pas recommandee en dehors d’un essai clinique. La chimiotherapie par la combinaison pemetrexed-cisplatine est le traitement de reference du MPM. Le bevacizumab est evalue dans l’essai de phase III MAPS qui doit se terminer fin 2013.
This paper references
Valproate–doxorubicin: promising therapy for progressing mesothelioma. A phase II study
A. Scherpereel (2010)
Photodynamic therapy and the evolution of a lung-sparing surgical treatment for mesothelioma.
J. Friedberg (2011)
WNT signaling in malignant mesothelioma.
S. Fox (2006)
Plasma Cell Membrane Localization of c-MET Predicts Longer Survival in Patients with Malignant Mesothelioma: A Series of 157 Cases from the MESOPATH Group
G. Levallet (2012)
Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma.
H. Kindler (2012)
Guidelines of the French Speaking Society for Chest Medicine for management of malignant pleural mesothelioma.
A. Scherpereel (2007)
The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma
Matthew J Bott (2011)
High frequency of inactivating mutations in the neurofibromatosis type 2 gene (NF2) in primary malignant mesotheliomas.
A. Bianchi (1995)
The European mesothelioma epidemic
J. Peto (1999)
Germline BAP1 mutations predispose to malignant mesothelioma
J. Testa (2011)
Biomarkers for mesothelioma
A. Scherpereel (2007)
Evolution of pleural cancers and malignant pleural mesothelioma incidence in France between 1980 and 2005
N. Le Stang (2010)
Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study
T. Treasure (2011)
Pemetrexed plus carboplatin in elderly patients with malignant pleural mesothelioma: combined analysis of two phase II trials
G. Ceresoli (2008)
The French National Mesothelioma Surveillance Program
M. Goldberg (2006)
Trimodality therapy for malignant pleural mesothelioma: results from an EORTC phase II multicentre trial
P. V. Van Schil (2010)
Malignant pleural mesothelioma: an update on biomarkers and treatment.
M. Ray (2009)
Population-based survival for malignant mesothelioma after introduction of novel chemotherapy
R. Damhuis (2011)
Initial Analysis of the International Association For the Study of Lung Cancer Mesothelioma Database
V. Rusch (2012)
Does positron emission tomography offer prognostic information in malignant pleural mesothelioma?
S. Sharif (2011)
Diffuse Pleural Mesothelioma and Asbestos Exposure in the North Western Cape Province
J. Wagner (1960)
Inactivation of p16INK4a expression in malignant mesothelioma by methylation.
L. Wong (2002)
A survey of opinions and beliefs concerning surgery for malignant pleural mesothelioma amongst 802 members of the European Association for Cardio-Thoracic Surgery (EACTS), the European Society of Thoracic Surgeons (ESTS) and the Society of Thoracic Surgeons (STS).
T. Treasure (2011)
Cancer environnemental : le mésothéliome pleural
J. Margery (2008)
A Systematic Review of Extrapleural Pneumonectomy for Malignant Pleural Mesothelioma
C. Cao (2010)
Prognostic Factors in the Treatment of Malignant Pleural Mesothelioma at a Large Tertiary Referral Center
R. Flores (2007)
Pemetrexed Maintenance Therapy in Patients with Malignant Pleural Mesothelioma
D. P. M. van den Bogaert (2006)
Prevention of malignant seeding after invasive diagnostic procedures in patients with pleural mesothelioma. A randomized trial of local radiotherapy.
C. Boutin (1995)
Suppression of pro-metastasis phenotypes expression in malignant pleural mesothelioma by the PI3K inhibitor LY294002 or the MEK inhibitor UO126.
G. Cole (2006)
Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma
A. Scherpereel (2009)
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.
N. Vogelzang (2003)
Second-line chemotherapy in malignant pleural mesothelioma: results of a retrospective multicenter survey.
P. Zucali (2012)
Statistical validation of the EORTC prognostic model for malignant pleural mesothelioma based on three consecutive phase II trials.
D. Fennell (2005)
Traitement de seconde ligne dans le mésothéliome pleural malin. Étude rétrospective française (2005–2006)
J. Margery (2010)

Semantic Scholar Logo Some data provided by SemanticScholar